China Rolls Out Nationwide 30-Day IND Pathway For Innovative Medicines

Positive Views From Local, Foreign Firms

 
• By Xu Hu
  
Shortened path
China's NMPA launches 30-day IND pathway after completing a one-year pilot in July (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from China